Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVR AlloVir	$7.07 +7.1%	$9.39	$7.96 ▼ $24.15	$49.48M	0.63	16,056 shs	39,763 shs
AMGN Amgen	$291.09 +3.9%	$304.54	$253.30 ▼ $346.85	$156.38B	0.59	2.76 million shs	6.05 million shs
BGNE BeiGene		$194.32	$126.97 ▼ $248.16	$18.03B	0.57	290,033 shs	331,608 shs
BMY Bristol-Myers Squibb	$53.80 +1.4%	$58.07	$39.35 ▼ $63.33	$109.47B	0.41	12.87 million shs	24.32 million shs
GILD Gilead Sciences	$105.25 +2.0%	$108.17	$62.07 ▼ $119.96	$131.05B	0.32	7.46 million shs	19.22 million shs
JSPR Jasper Therapeutics	$3.62 +4.3%	$5.28	$3.13 ▼ $29.36	$54.38M	2.55	281,579 shs	238,602 shs
NVS Novartis	$104.04 +2.0%	$108.95	$92.35 ▼ $120.92	$212.66B	0.56	1.54 million shs	3.60 million shs
RCUS Arcus Biosciences	$7.94 +12.8%	$9.92	$6.50 ▼ $18.98	$834.80M	1.54	767,884 shs	1.68 million shs
VIGL Vigil Neuroscience	$1.49 +6.4%	$2.22	$1.31 ▼ $6.06	$73.19M	1.94	471,403 shs	84,014 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVR AlloVir	+7.12%	-11.63%	-23.15%	-31.66%	-58.68%
AMGN Amgen	+3.86%	-4.78%	-11.08%	+10.17%	+7.67%
BGNE BeiGene	0.00%	0.00%	0.00%	0.00%	+19.93%
BMY Bristol-Myers Squibb	+1.57%	-9.72%	-14.61%	-5.20%	+4.26%
GILD Gilead Sciences	+2.00%	-5.93%	-10.20%	+18.07%	+50.49%
JSPR Jasper Therapeutics	+4.32%	-14.42%	-31.44%	-48.21%	-87.76%
NVS Novartis	+2.20%	-6.11%	-9.92%	+3.79%	+8.60%
RCUS Arcus Biosciences	+13.33%	+0.63%	-15.70%	-47.00%	-54.52%
VIGL Vigil Neuroscience	+6.43%	-15.82%	-37.92%	-19.02%	-54.98%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALVR AlloVir	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AMGN Amgen	4.3266 of 5 stars	2.2	4.0	3.3	3.9	3.5	2.5	0.6
BGNE BeiGene	1.1613 of 5 stars	3.4	0.0	0.0	0.0	0.0	0.8	0.6
BMY Bristol-Myers Squibb	3.7672 of 5 stars	1.2	3.0	4.2	4.0	3.5	3.3	0.0
GILD Gilead Sciences	4.5068 of 5 stars	2.4	4.0	1.7	4.1	3.5	2.5	1.9
JSPR Jasper Therapeutics	2.701 of 5 stars	3.5	4.0	0.0	0.0	2.5	1.7	0.6
NVS Novartis	2.839 of 5 stars	1.9	5.0	2.5	0.0	3.4	0.0	1.9
RCUS Arcus Biosciences	2.4824 of 5 stars	3.5	1.0	0.0	0.0	3.3	4.2	0.0
VIGL Vigil Neuroscience	3.5962 of 5 stars	3.5	5.0	0.0	0.0	2.1	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVR AlloVir	0.00	N/A	N/A	N/A
AMGN Amgen	2.48	Hold	$315.22	8.29% Upside
BGNE BeiGene	2.83	Moderate Buy	$253.92	∞ Upside
BMY Bristol-Myers Squibb	2.32	Hold	$57.67	7.19% Upside
GILD Gilead Sciences	2.72	Moderate Buy	$105.12	-0.12% Downside
JSPR Jasper Therapeutics	3.00	Buy	$62.50	1,626.52% Upside
NVS Novartis	1.80	Reduce	$123.38	18.58% Upside
RCUS Arcus Biosciences	3.00	Buy	$30.25	280.98% Upside
VIGL Vigil Neuroscience	3.00	Buy	$16.25	990.60% Upside

Current Analyst Ratings Breakdown

Latest GILD, AMGN, BMY, NVS, BGNE, JSPR, VIGL, ALVR, and RCUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/9/2025	AMGN Amgen	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$328.00 ➝ $330.00
4/8/2025	BMY Bristol-Myers Squibb	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$67.00 ➝ $55.00
3/27/2025	GILD Gilead Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$120.00 ➝ $130.00
3/14/2025	VIGL Vigil Neuroscience	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$24.00 ➝ $13.00
3/14/2025	VIGL Vigil Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $14.00
3/11/2025	GILD Gilead Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$123.00 ➝ $130.00
3/11/2025	JSPR Jasper Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
3/5/2025	AMGN Amgen	Johnson Rice Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$294.00
3/5/2025	AMGN Amgen	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$275.00 ➝ $294.00
3/5/2025	GILD Gilead Sciences	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$116.00 ➝ $126.00
3/5/2025	GILD Gilead Sciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$120.00 ➝ $140.00

(Data available from 4/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVR AlloVir	N/A	N/A	N/A	N/A	$29.35 per share	N/A
AMGN Amgen	$33.42B	4.68	$29.17 per share	9.98	$10.93 per share	26.63
BGNE BeiGene	$3.32B	0.00	N/A	N/A	$37.10 per share	0.00
BMY Bristol-Myers Squibb	$48.30B	2.27	$5.68 per share	9.48	$8.08 per share	6.66
GILD Gilead Sciences	$28.75B	4.56	$8.31 per share	12.66	$15.44 per share	6.82
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$7.03 per share	N/A
NVS Novartis	$51.72B	4.11	$10.37 per share	10.03	$21.59 per share	4.82
RCUS Arcus Biosciences	$258M	3.24	N/A	N/A	$6.17 per share	1.29
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	$3.24 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVR AlloVir	-$190.42M	-$20.23	N/A	∞	N/A	N/A	-71.03%	-61.27%	5/12/2025 (Estimated)
AMGN Amgen	$4.09B	$7.55	38.56	13.61	2.63	12.24%	176.32%	11.71%	5/1/2025 (Estimated)
BGNE BeiGene	-$881.71M	-$8.24	N/A	N/A	N/A	-25.94%	-25.12%	-14.95%	N/A
BMY Bristol-Myers Squibb	-$8.95B	-$4.42	N/A	8.83	2.07	-18.53%	13.93%	2.46%	4/24/2025 (Estimated)
GILD Gilead Sciences	$480M	$0.37	284.46	12.98	0.71	1.67%	31.63%	10.38%	4/24/2025 (Estimated)
JSPR Jasper Therapeutics	-$64.46M	-$4.86	N/A	N/A	N/A	N/A	-67.64%	-58.53%	5/13/2025 (Estimated)
NVS Novartis	$11.94B	$5.88	17.69	11.81	1.70	23.56%	37.24%	15.85%	4/22/2025 (Estimated)
RCUS Arcus Biosciences	-$307M	-$3.10	N/A	N/A	N/A	-102.66%	-45.59%	-22.38%	5/6/2025 (Estimated)
VIGL Vigil Neuroscience	-$82.64M	-$2.06	N/A	N/A	N/A	N/A	-83.89%	-65.34%	5/6/2025 (Estimated)

Latest GILD, AMGN, BMY, NVS, BGNE, JSPR, VIGL, ALVR, and RCUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	VIGL Vigil Neuroscience	-$0.53	N/A	N/A	N/A	N/A	N/A
5/1/2025	Q1 2025	AMGN Amgen	$4.18	N/A	N/A	N/A	$8.05 billion	N/A
4/24/2025	Q1 2025	BMY Bristol-Myers Squibb	$1.55	N/A	N/A	N/A	$10.77 billion	N/A
4/24/2025	Q1 2025	GILD Gilead Sciences	$1.73	N/A	N/A	N/A	$6.77 billion	N/A
4/22/2025	Q1 2025	NVS Novartis	$2.07	N/A	N/A	N/A	$12.92 billion	N/A
3/13/2025	Q4 2024	VIGL Vigil Neuroscience	-$0.49	-$0.57	-$0.08	-$0.57	N/A	N/A
2/27/2025	Q4 2024	JSPR Jasper Therapeutics	-$1.27	-$1.62	-$0.35	-$1.62	N/A	N/A
2/25/2025	Q4 2024	RCUS Arcus Biosciences	-$1.17	-$1.03	+$0.14	-$1.03	$29.38 million	$36.00 million
2/11/2025	Q4 2024	GILD Gilead Sciences	$1.67	$1.90	+$0.23	$1.42	$7.15 billion	N/A
2/6/2025	Q4 2024	BMY Bristol-Myers Squibb	$1.47	$1.67	+$0.20	$0.04	$11.57 billion	N/A
2/4/2025	Q4 2024	AMGN Amgen	$5.04	$5.31	+$0.27	$1.16	$8.87 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVR AlloVir	N/A	N/A	N/A	N/A	N/A
AMGN Amgen	$9.52	3.27%	+8.53%	126.09%	14 Years
BGNE BeiGene	N/A	N/A	N/A	N/A	N/A
BMY Bristol-Myers Squibb	$2.48	4.61%	+6.38%	N/A	17 Years
GILD Gilead Sciences	$3.16	3.00%	+2.74%	854.05%	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
NVS Novartis	$2.51	2.41%	+5.34%	42.69%	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	N/A

Latest GILD, AMGN, BMY, NVS, BGNE, JSPR, VIGL, ALVR, and RCUS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/4/2025	AMGN Amgen	quarterly	$2.38	3.05%	5/16/2025	5/16/2025	6/6/2025
3/3/2025	BMY Bristol-Myers Squibb	quarterly	$0.62	4.14%	4/4/2025	4/4/2025	5/1/2025
2/5/2025	GILD Gilead Sciences	quarterly	$0.79	3%	3/14/2025	3/14/2025	3/28/2025
2/20/2025	NVS Novartis		$3.8695		3/12/2025	3/12/2025	3/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVR AlloVir	N/A	86.78	86.78
AMGN Amgen	9.62	1.26	0.95
BGNE BeiGene	0.05	1.93	1.72
BMY Bristol-Myers Squibb	2.90	1.25	1.15
GILD Gilead Sciences	1.24	1.50	1.20
JSPR Jasper Therapeutics	N/A	7.61	7.61
NVS Novartis	0.48	1.04	0.84
RCUS Arcus Biosciences	0.08	5.24	5.24
VIGL Vigil Neuroscience	N/A	3.72	3.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVR AlloVir	66.05%
AMGN Amgen	76.50%
BGNE BeiGene	48.55%
BMY Bristol-Myers Squibb	76.41%
GILD Gilead Sciences	83.67%
JSPR Jasper Therapeutics	79.85%
NVS Novartis	13.12%
RCUS Arcus Biosciences	92.89%
VIGL Vigil Neuroscience	83.64%

Insider Ownership

Company	Insider Ownership
ALVR AlloVir	32.07%
AMGN Amgen	0.69%
BGNE BeiGene	7.43%
BMY Bristol-Myers Squibb	0.09%
GILD Gilead Sciences	0.16%
JSPR Jasper Therapeutics	2.70%
NVS Novartis	0.01%
RCUS Arcus Biosciences	12.30%
VIGL Vigil Neuroscience	33.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVR AlloVir	110	5.04 million	3.43 million	Optionable
AMGN Amgen	28,000	537.21 million	533.50 million	Optionable
BGNE BeiGene	9,000	97.62 million	90.20 million	Optionable
BMY Bristol-Myers Squibb	34,300	2.03 billion	2.03 billion	Optionable
GILD Gilead Sciences	17,000	1.25 billion	1.24 billion	Optionable
JSPR Jasper Therapeutics	20	15.02 million	14.60 million	Optionable
NVS Novartis	101,700	2.04 billion	2.04 billion	Optionable
RCUS Arcus Biosciences	500	105.14 million	80.26 million	Optionable
VIGL Vigil Neuroscience	40	49.12 million	27.38 million	Not Optionable

GILD, AMGN, BMY, NVS, BGNE, JSPR, VIGL, ALVR, and RCUS Headlines

Recent News About These Companies

Blair William & Co. IL Buys Shares of 323,900 Vigil Neuroscience, Inc. (NASDAQ:VIGL)

April 6, 2025 | marketbeat.com

Vigil presents data on oral small molecule program including VG-3927

April 3, 2025 | markets.businessinsider.com

William Blair Remains a Buy on Vigil Neuroscience Inc (VIGL)

April 3, 2025 | markets.businessinsider.com

Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

April 2, 2025 | globenewswire.com

Vigil Neuroscience Reports 2024 Results and Clinical Progress

April 2, 2025 | tipranks.com

Vigil Neuroscience files to sell 5.38M shares of common stock for holders

April 1, 2025 | markets.businessinsider.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Large Drop in Short Interest

March 31, 2025 | marketbeat.com

Vigil Neuroscience (VIGL) to Release Earnings on Tuesday

March 18, 2025 | marketbeat.com

Vigil Neuroscience (VIGL) Upgraded to Buy: Here's What You Should Know

March 17, 2025 | zacks.com

FY2029 Earnings Forecast for VIGL Issued By Wedbush

March 17, 2025 | marketbeat.com

Q1 Earnings Estimate for VIGL Issued By William Blair

March 17, 2025 | marketbeat.com

Wedbush Issues Pessimistic Forecast for Vigil Neuroscience (NASDAQ:VIGL) Stock Price

March 15, 2025 | marketbeat.com

Vigil Neuroscience (NASDAQ:VIGL) Given New $14.00 Price Target at HC Wainwright

March 15, 2025 | marketbeat.com

Vigil Neuroscience price target lowered to $14 from $17 at H.C. Wainwright

March 14, 2025 | markets.businessinsider.com

Vigil Neuroscience price target lowered to $13 from $24 at Wedbush

March 14, 2025 | markets.businessinsider.com

Vigil Neuroscience (NASDAQ:VIGL) Announces Earnings Results

March 14, 2025 | marketbeat.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update

March 14, 2025 | marketbeat.com

Vigil Neuroscience Faces Market Risks from Preferred Stock Issuance and Potential Share Dilution

March 14, 2025 | tipranks.com

Vigil Neuroscience, Inc.: Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates

March 13, 2025 | finanznachrichten.de

Vigil Neuroscience reports Q4 EPS (57c), consensus (47c)

March 13, 2025 | markets.businessinsider.com

Vigil Neuroscience sees cash runway into 2026

March 13, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GILD, AMGN, BMY, NVS, BGNE, JSPR, VIGL, ALVR, and RCUS Company Descriptions

AlloVir NASDAQ:ALVR

$7.07 +0.47 (+7.12%)

As of 04/8/2025

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Amgen NASDAQ:AMGN

$291.09 +10.83 (+3.86%)

Closing price 04/9/2025 04:00 PM Eastern

Extended Trading

$294.42 +3.34 (+1.15%)

As of 04/9/2025 06:42 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

BeiGene NASDAQ:BGNE

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Bristol-Myers Squibb NYSE:BMY

$53.80 +0.73 (+1.38%)

Closing price 04/9/2025 03:59 PM Eastern

Extended Trading

$53.62 -0.17 (-0.33%)

As of 04/9/2025 06:42 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Gilead Sciences NASDAQ:GILD

$105.25 +2.06 (+2.00%)

Closing price 04/9/2025 04:00 PM Eastern

Extended Trading

$105.58 +0.33 (+0.31%)

As of 04/9/2025 06:42 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Jasper Therapeutics NASDAQ:JSPR

$3.62 +0.15 (+4.32%)

Closing price 04/9/2025 04:00 PM Eastern

Extended Trading

$3.62 0.00 (0.00%)

As of 04/9/2025 05:01 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Novartis NYSE:NVS

$104.04 +2.08 (+2.04%)

Closing price 04/9/2025 03:59 PM Eastern

Extended Trading

$105.50 +1.46 (+1.40%)

As of 04/9/2025 06:22 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Arcus Biosciences NYSE:RCUS

$7.94 +0.90 (+12.78%)

Closing price 04/9/2025 03:59 PM Eastern

Extended Trading

$7.97 +0.03 (+0.37%)

As of 04/9/2025 06:21 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Vigil Neuroscience NASDAQ:VIGL

$1.49 +0.09 (+6.43%)

Closing price 04/9/2025 04:00 PM Eastern

Extended Trading

$1.50 +0.01 (+0.67%)

As of 04/9/2025 06:22 PM Eastern

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GILD, AMGN, BMY, NVS, BGNE, JSPR, VIGL, ALVR, and RCUS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GILD, AMGN, BMY, NVS, BGNE, JSPR, VIGL, ALVR, and RCUS Earnings

Compare Dividends

Latest GILD, AMGN, BMY, NVS, BGNE, JSPR, VIGL, ALVR, and RCUS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GILD, AMGN, BMY, NVS, BGNE, JSPR, VIGL, ALVR, and RCUS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GILD, AMGN, BMY, NVS, BGNE, JSPR, VIGL, ALVR, and RCUS Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools